Unique ID issued by UMIN | UMIN000010485 |
---|---|
Receipt number | R000012258 |
Scientific Title | Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma |
Date of disclosure of the study information | 2013/04/15 |
Last modified on | 2013/04/13 11:10:08 |
Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma
Biweekly THP-COP for PTCLs
Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma
Biweekly THP-COP for PTCLs
Japan |
Peripheral T-cell lymphoma, not otherwise specified and angioimmunoblastic T-cell lymphoma
Hematology and clinical oncology |
Malignancy
NO
Establishment of new standard therapy in PTCLs
Safety,Efficacy
Phase II
response rate and safety
progression-free survival and overall survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Medicine |
Six cycles of biweekly THP-COP therapy between 2004 and 2011.
15 | years-old | <= |
70 | years-old | > |
Male and Female
a. Consecutive new diagnoses with measurable disease representing histologically documented PTCL-nos or AITL according to the World Health Organization classification;
b. pre-study performance status PS score ranging from 0 to 3 on the Eastern Cooperative Oncology Group;
c. 15-69 years of age;
d. any clinical stage;
e. knowledge about their diagnosis and expected prognosis
f. a left ventricular ejection fraction by echocardiography at least 50%
g. a partial pressure of oxygen in the arterial blood at least 60 Torr while breathing ambient air.
h. written informed conscent
Exclusion criteria were the presence of serious infection; active tuberculosis; diabetes mellitus uncontrollable with insulin, liver cirrhosis, arrhythmia, or other abnormal electrocardiographic finding requiring treatment, concomitant malignant disease other than basal cell carcinoma of the skin or carcinoma in situ of the uteric cervix; central nervous system (CNS) lymphoma; pregnancy or breast feeding; mental disorders; and positivity for hepatitis B surface antigen, human T-lymphotrophic virus-1 antibody, or human immunodeficiency virus antibody. Patients were also excluded if the treating physician considered the protocol too difficult for the patients to carry out.
20
1st name | |
Middle name | |
Last name | NAOTO TOMITA |
Yokohama City University
Department of Internal Medicine and Clinical Immunology
3-9 Fukuura, Kanazawa, Yokohama
1st name | |
Middle name | |
Last name |
Yokohama City University
Department of Internal Medicine and Clinical Immunology
3-9 Fukuura, Kanazawa, Yokohama
Yokohama City University Hopsital
None
Other
NO
2013 | Year | 04 | Month | 15 | Day |
Unpublished
Completed
2003 | Year | 03 | Month | 14 | Day |
2003 | Year | 04 | Month | 01 | Day |
2013 | Year | 04 | Month | 13 | Day |
2013 | Year | 04 | Month | 13 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000012258
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |